Fujifilm Introduces AI-Powered Chest X-Ray Software in Collaboration with Lunit
By MedImaging International staff writers Posted on 17 Aug 2021 |
Illustration
Fujifilm Corporation (Tokyo, Japan) has announced that its software for analyzing chest X-ray developed with the core artificial intelligence (AI) technology of Lunit (Seoul, Korea) will be commercially available across Japan.
The AI-powered product named CXR-AID is designed to better detect major abnormal findings such as chest nodule, consolidation, and pneumothorax from chest X-ray images. Findings detected by the AI software are shown in color as a heatmap display, with each score included. Through this solution, doctors and medical professionals are able to reduce missed cases and effectively diagnose chest diseases from chest X-ray.
The PMDA approved AI-powered software is developed with Lunit’s core AI technology and is provided with Fujifilm's PACS system(SYNAPSE) and to be distributed across hospitals and medical institutions of Japan for more efficient diagnosis. With Lunit AI connected to Fujifilm's PACS system and X-ray devices, the AI products are distributed across its global customers and networks.
Lunit AI is also applied in Fujifilm's mobile X-ray device (FDR nano) and portable X-ray devices (FDR Xair), General X-ray device (FDR Smart X), and is in use in clinical settings to detect COVID-19 symptoms and tuberculosis in regions where there are a limited number of doctors.
"We strongly believe that sooner or later AI will become the new standard of care, and AI will be used everywhere as a must-use product," said Brandon Suh, CEO of Lunit. "Not only will it be used as a tool to make the workflow more efficient, but it will ensure better diagnosis and healthier life for patients. We are glad to make this happen with Fujifilm, and will accelerate our expansion with its global network."
Related Links:
Fujifilm Corporation
Lunit
The AI-powered product named CXR-AID is designed to better detect major abnormal findings such as chest nodule, consolidation, and pneumothorax from chest X-ray images. Findings detected by the AI software are shown in color as a heatmap display, with each score included. Through this solution, doctors and medical professionals are able to reduce missed cases and effectively diagnose chest diseases from chest X-ray.
The PMDA approved AI-powered software is developed with Lunit’s core AI technology and is provided with Fujifilm's PACS system(SYNAPSE) and to be distributed across hospitals and medical institutions of Japan for more efficient diagnosis. With Lunit AI connected to Fujifilm's PACS system and X-ray devices, the AI products are distributed across its global customers and networks.
Lunit AI is also applied in Fujifilm's mobile X-ray device (FDR nano) and portable X-ray devices (FDR Xair), General X-ray device (FDR Smart X), and is in use in clinical settings to detect COVID-19 symptoms and tuberculosis in regions where there are a limited number of doctors.
"We strongly believe that sooner or later AI will become the new standard of care, and AI will be used everywhere as a must-use product," said Brandon Suh, CEO of Lunit. "Not only will it be used as a tool to make the workflow more efficient, but it will ensure better diagnosis and healthier life for patients. We are glad to make this happen with Fujifilm, and will accelerate our expansion with its global network."
Related Links:
Fujifilm Corporation
Lunit
Latest Industry News News
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures
- Global Contrast Enhanced Ultrasound Market Driven by Demand for Early Detection of Chronic Diseases